Alessandro D. Santin, MD

Professor of Obstetrics, Gynecology, and Reproductive Sciences; Disease Aligned Research Team Leader, Gynecologic Oncology Program, Yale Cancer Center; Co-Chief, Section of Gynecologic Oncology

Clinical Interests

  • Medical Oncology

Patient Care

Accepts new patients? Yes
Patient Type: Adult; Child
Referrals: From patients or physicians

Patient Care Organizations

Obstetrics, Gynecology & Reproductive Sciences: Discovery to Cure | Gynecologic Oncology: Ovarian Cancer Early Detection Program

Yale Cancer Center: Gynecologic Oncology Program

Yale Medicine

Office of Cooperative Research

Clinical Trials

Conditions Study Title
Ovary A Randomized, Open-label, Multicenter, Phase 3 Study To Evaluate The Efficacy And Safety Of Avelumab (msb0010718c) In Combination With And/or Following Chemotherapy In Patients With Previously Untreated Epithelial Ovarian Cancer
Ovary A Randomized Phase II Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab in Recurrent or Persistent Platinum-resistant/Refractory Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers
Other Female Genital A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
Ovary A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients With HRD-Positive Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
Corpus Uteri A phase II evaluation of pembrolizumab, a fully human antibody against PD-1, in the treatment of persistent or recurrent hypermutated/ultramutated endometrial cancer identified by next generation sequencing (NGS) and comprehensive genomic profiling (CGP), A Pilot Study
Other Female Genital, Other Urinary, Ovary A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Anus, Bladder, Bones and Joints, Brain and Nervous System, Breast - Female, Breast - Male, Cervix Uteri, Colon, Corpus Uteri, Esophagus, Eye and Orbit, Hodgkin's Lymphoma, Kaposi's sarcoma, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Liver, Lung, Lymphoid Leukemia, Melanoma, skin, Non-Hodgkin's Lymphoma, Other Digestive Organ, Other Endocrine System, Other Female Genital, Other Male Genital, Other Respiratory and Intrathoracic Organs, Other Skin, Other Urinary, Ovary, Pancreas, Prostate, Rectum, Small Intestine, Soft Tissue, Stomach, Thyroid NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas
Cervix Uteri Treatment of High-Grade Pre-Neoplastic Cervical Lesions (CIN 2/3) Using a Novel "Prime and Pull" Strategy
Bladder, Other Urinary, Phase I A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4
Corpus Uteri, Other Female Genital A Phase II Evaluation of Afatinib
Ovary Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Edit this profile

Contact Info

Alessandro D. Santin, MD
Patient Care Location
Yale Gynecologic OncologySmilow Cancer Hospital at Yale New Haven
35 Park Street, Ste 1st floor

New Haven, CT 06511
View on map...
Mailing Address
Yale Gynecologic OncologyPO Box 208063
New Haven, CT 06520-8063